Tag: Gleason

ProtecT trial shows classical risk categories don’t help

EAU17: ProtecT trial shows classical risk categories don’t help

The classical risk categories used to stage prostate cancer disease do not aid clinical decision-making as much as PSA, biopsy, Gleason score, biopsy results and other measurements, according to an expert who commented during the Late-Breaking news segment of...

EMUC16: Re-thinking active surveillance strategies in PCa

With the emergence of more precise imaging and new results from genomic investigations, onco-urology experts are challenging standard medical strategies and are re-thinking their treatment regimens to achieve better patient care. At the concluding session of the 8th European...
SEEM16 Turkeri crowd

[SEEM16] mpMRI: A more accurate alternative to biopsy?

Multiparametric MRI (mpMRI) can help prevent overdiagnosis of prostate cancer. It can potentially replace biopsy in active surveillance, help avoid biopsies in low-risk patients with normal MRI, and reduce the number of cores per biopsy in prostate cancer treatment....
Mark Emberton Using MRI before biopsy: A divisive topic?

Using MRI before biopsy: A divisive topic?

Emerging technologies trigger new approaches. But with the perceived benefits of novel discoveries come the expected criticisms and contrary viewpoints. The issue of Magnetic Resonance Imaging (MRI) has prompted closer examination from both its adherents and critics during Thematic...

EMUC15: Examining new issues and challenges in prostate cancer

From precision grading, imaging, genomics to epidemiology, a range of issues that impact prostate cancer therapies were examined by a multidisciplinary team of experts which gathered today in Barcelona for the 7th European Multidisciplinary Meeting on Urological Cancers (EMUC15)....

EAU15: mCRPC looks at novel research

Much research has been done on new treatment modalities for patients with metastatic castration-resistant prostate cancer (mCRPC) but the cross resistance between these therapies needs to be understood better. Another relative new topic of research is the quality of...

Are there useable molecular markers for prostate cancer?

There is no doubt that we need more and better markers to determine risk, presence, aggressiveness and therapy response of prostate cancer (PCa). Besides physical symptoms such as palpable irregularities upon digital rectal examination (DRE), current indicators range from...

Where do we stand with predictive biomarkers in mCRPC?

Treatment options for men with metastatic castrationresistant prostate cancer (mCRPC) have expanded with the introduction of several new approved agents including abiraterone, enzalutamide, cabazitaxel and radium-2231-6. With evidence that both abiraterone acetate and enzalutamide are effective agents when administered...